<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125989">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01805674</url>
  </required_header>
  <id_info>
    <org_study_id>ESTROCALVI</org_study_id>
    <nct_id>NCT01805674</nct_id>
  </id_info>
  <brief_title>Isoflavones and Magnolia Extract in the Quality of Life in Menopausal Women</brief_title>
  <acronym>ESTROCALVI</acronym>
  <official_title>Study to Evaluate the Changes in Quality of Life in Menopausal Women After the Administration of Soy Isoflavones Combined With Magnolia Extract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm Spain</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In menopause, the vasomotor symptomatology, accompanied or less by affective and behavioural
      symptoms, globally worsens the quality of daily life.

      The improvement of the quality could be reached with adequate food supplements, named
      phytoestrogens, in particular Soy Isoflavones (SI), which are natural substances with
      estrogen-like and estrogen-antagonistic activity, which are active in the control of
      menopausal vasomotor symptoms. Besides, combined with magnolia extract it could improve the
      psychological symptomatology also improving the quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>the quality of life measured by the scale of Cervantes</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Cervantes scale is a Spanish validated questionnaire specific for measure the quality of life in menopausal women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical changes in vasomotor symptomatology</measure>
    <time_frame>baseline, 2, 4, 8 and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>In a semiquantitative scale of intensity the vasomotor, psychological and sexual symptomatology will be evaluated in each visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>isoflavones combined with magnolia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>isoflavones combined with magnolia</intervention_name>
    <description>1 tablet/day duration: 12 weeks</description>
    <arm_group_label>isoflavones combined with magnolia</arm_group_label>
    <other_name>Estromineral Serena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with at least 12 months of amenorrhea

          -  Presence of 1 or more vasomotor symptoms as hot flushing, nocturnal sweating or
             palpitations

          -  One or more psychological symptoms as insomnia, irritability, anxiety, depressed
             mood. Also with concomitant symptoms of sexual area as reduction of libido and
             vaginal dryness.

          -  Women must give the informed consent

        Exclusion Criteria:

          -  clinical history of medical or surgical pathologies that could affect the results of
             the study, including serious cardiovascular, metabolic, kidney or liver diseases

          -  Patients with the habit of eating soy foods or dietary supplements with soy extract

          -  patients diagnosed with breast or uterine mass (neoplasia hormone sensitive)

          -  patients that were treated with estrogens (HRT or phytoestrogens)in the 2 months
             before the beginning of the study.

          -  patients with treatment with antibiotics, antidepressant and/or anxiolytic products
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Anguera, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rottapharm S.L.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Sánchez-Borrego, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Médico Teknon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grupo hospitalario Quirón</name>
      <address>
        <city>Erandio</city>
        <state>Vizcaya</state>
        <zip>48950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Celis, MD</last_name>
      <email>ricardocelisgarcia@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Celis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Médico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Sánchez-Borrego, MD</last_name>
      <email>rschez.borrego@diatros.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Sánchez-Borrego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Somdex S.L.</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Porqueras, MD</last_name>
      <email>rosa.porqueras@santiagodexeus.com</email>
    </contact>
    <investigator>
      <last_name>Rosa Porqueras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgery of Dr. Sánchez Muñoz</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Sánchez Muñoz, MD</last_name>
      <email>sanmunoz@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Sánchez Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabinete Médico Velazquez</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Ojeda, MD</last_name>
      <email>ginecologia@gabinetemedicovelazquez.com</email>
    </contact>
    <investigator>
      <last_name>Dolores Ojeda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica ginecológica Cecchini</name>
      <address>
        <city>Oviedo</city>
        <zip>33004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Gutiérrez Cecchini, MD, PhD</last_name>
      <email>Cechini@telecable.es</email>
    </contact>
    <investigator>
      <last_name>Carmen Gutiérrez Cecchini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Sevillano de Ginecología y Obstetricia</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Mª de Lizaur, MD</last_name>
      <email>alizaur@insego.es</email>
    </contact>
    <investigator>
      <last_name>Ana Mª de Lizaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgery of Dr. Mahiques</name>
      <address>
        <city>Valencia</city>
        <zip>46006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Mahiques, MD, PhD</last_name>
      <email>pedromahiques@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Mahiques, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgery of Dr. Raga</name>
      <address>
        <city>Valencia</city>
        <zip>46006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Raga, MD, PhD</last_name>
      <email>francisco.raga@uv.es</email>
    </contact>
    <investigator>
      <last_name>Francisco Raga, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Ginecológico Dr. García Pérez-Llantada SL</name>
      <address>
        <city>Zaragoza</city>
        <zip>50008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier García Pérez-Llantada, MD, PhD</last_name>
      <email>consulta@llantada.com</email>
    </contact>
    <investigator>
      <last_name>Javier García Pérez-Llantada, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 5, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>quality of life</keyword>
  <keyword>soy isoflavones</keyword>
  <keyword>magnolia extract</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
